Von Willebrand Disease (VWD) Treatments
Find Von Willebrand Disease (VWD) Treatments
Brand Name
Altuviiio
Generic Name
Fc-VWF-XTEN
View Brand Information FDA approval date: February 22, 2023
Form: Kit
What is Altuviiio (Fc-VWF-XTEN)?
ALTUVIIIO [antihemophilic factor , Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A for: Routine prophylaxis to reduce the frequency of bleeding episodes On-demand treatment and control of bleeding episodes Perioperative management of bleeding ALTUVIIIO [antihemophilic factor , Fc-VWF-XTEN fusion protein-ehtl] is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A for: Routine prophylaxis to reduce the frequency of bleeding episodes On-demand treatment & control of bleeding episodes Perioperative management of bleeding Limitation of Use: ALTUVIIIO is not indicated for the treatment of von Willebrand disease. Limitation of Use ALTUVIIIO is not indicated for the treatment of von Willebrand disease.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment